In conclusion, while our study provides compelling evidence for the potential of Aurora A and AKT inhibitors combined with radiation therapy in colon cancer cells, further validation through in vivo models and clinical studies will be necessary to fully assess its therapeutic relevance and safety profile. This evidence concerns the gene AKT1 and colonic neoplasm.